atherosclerosis | GenomeWeb

atherosclerosis

The researchers will use TwoXar's software to predict potential candidates for atherosclerosis drugs and test them in pre-clinical studies.

The company's pipeline consists of tests for early detection of Alzheimer's and atherosclerosis as well as for guiding statin therapy.

Interleukin will provide its genetic tests for inflammatory and metabolic diseases for a study directed at a cardiovascular disease drug in development.

NEW YORK (GenomeWeb) – Cofactor Genomics said on Thursday it has won a contract from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute to identify sites of epigenetic modifications that contribute to cardiovascular disease endpoints.

NEW YORK (GenomeWeb) – New data published this month by researchers from Regulus Therapeutics and academic collaborators show that long-term therapeutic silencing of microRNA-33 could result in a number of deleterious effects in mice including fatty liver and elevated triglyceride levels.

NEW YORK (GenomeWeb News) – Global Genomics Group and Quintiles announced today a collaboration aimed at developing new diagnostic tools and treatments for cardiovascular diseases as part of the Genetic Loci and Burden of Atherosclerotic Lesions (GLOBAL) clinical study.

A team led by Emory University researchers this week published new data showing that a specific microRNA plays a key role in the development of atherosclerosis in a mouse model of the disease, and that inhibiting its human homolog may have therapeutic potential.

NEW YORK (GenomeWeb News) – Illumina said today that it will partner with Global Genomics Group (G3) to provide whole-genome sequencing for the Genetic Loci and the Burden of Atherosclerotic Lesions, or GLOBAL, clinical trial.

The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

Regulus Therapeutics this week announced that it has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics against three exclusive targets.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.